Related Experiment Video
Updated: Jun 17, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic
Murtadha Al-Khabori1, Mark D Minden, Karen W L Yee
1Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.
Insights
Pediatric-based regimens, like DFCI, significantly improved relapse-free and overall survival for adults with T-cell acute lymphoblastic leukemia (T-ALL). Asparaginase-intensive protocols show superior efficacy in T-ALL treatment.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- T-cell acute lymphoblastic leukemia (T-ALL) is a rare and aggressive hematologic malignancy.
- Treatment strategies for adult T-ALL have historically yielded suboptimal outcomes compared to pediatric ALL.
- The efficacy of pediatric-inspired regimens in adult T-ALL requires further investigation.
Purpose of the Study:
- To compare the outcomes of adult T-ALL patients treated with conventional adult-based regimens versus a pediatric-based protocol.
- To evaluate the impact of asparaginase-intensive chemotherapy on survival in adult T-ALL.
Main Methods:
- Retrospective analysis of adult T-ALL patients treated at a single institution over 17 years (1990-2007).
- Comparison of two treatment groups: non-DFCI (adult-based regimens, 1990-2000) and DFCI (pediatric-based protocol, 2000-2007).
- Assessment of complete response rates, 3-year relapse-free survival (RFS), and overall survival (OS).
Main Results:
- No significant difference in complete response rates between the DFCI and non-DFCI groups.
- Significantly higher 3-year RFS and OS in the DFCI-treated group (p < 0.0001 and p = 0.0003, respectively).
- Treatment group (DFCI vs. non-DFCI) identified as a major prognostic factor for RFS and OS on multivariate analysis.
Conclusions:
- Asparaginase-intensive pediatric-based regimens demonstrate superior efficacy in adult T-ALL.
- The DFCI protocol, incorporating intensive asparaginase, significantly improves survival outcomes for adult T-ALL patients.
- These findings support the adoption of pediatric-inspired chemotherapy protocols for adult T-ALL treatment.
Abstract:
All patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and treated over a 17-year period at a single institution were retrospectively analyzed. From 1990 to 2000, 40 patients were treated with a variety of adult-based ALL regimens. From 2000 to 2007, a pediatric-based protocol, DFCI (Dana Farber Cancer Institute), was used as the standard regimen for all patients (n = 32). The two groups (DFCI and non-DFCI) had comparable baseline characteristics. Complete response rates were not significantly different between the DFCI- and non-DFCI-treated groups. The 3-year relapse free survival (RFS) and overall survival (OS) were significantly higher in the DFCI-treated group (p < 0.0001 and p = 0.0003, respectively). On multivariate analysis, the treatment group (DFCI vs. non-DFCI) was the major prognostic factor influencing both RFS and OS. The results provide evidence supporting the superior efficacy of asparaginase-intensive pediatric-based regimens for adults with T-ALL.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
02:56Treatment Resistent Cancers